Literature DB >> 9634321

Molecular events in uterine cervical cancer.

S A Southern1, C S Herrington.   

Abstract

OBJECTIVE: To review the literature regarding the molecular events which occur in the development of uterine cervical cancer, with particular reference to human papillomavirus (HPV) infection.
METHODOLOGY: Bibliographic searches of Medline and the ISI citation databases using appropriate keywords, including the following: papillomavirus, cervix, pathology, cyclin, chromosome, heterozygosity, telomerase, smoking, hormones, HLA, immune response, HIV, HSV, EBV.
CONCLUSIONS: It has become clear that most cervical neoplasia, whether intraepithelial or invasive, is attributable in part to HPV infection. However, HPV infection alone is not sufficient, and, in a small proportion of cases, may not be necessary for malignant transformation. There is increasing evidence that HPV gene products interfere with cell cycle control leading to secondary accumulation of small and large scale genetic abnormalities. This may explain the association of viral persistence with lesion progression but, in many patients, secondary factors, such as smoking and immune response, are clearly important. However, the mechanisms involved in the interaction between HPV and host factors are poorly understood.

Entities:  

Mesh:

Year:  1998        PMID: 9634321      PMCID: PMC1758096          DOI: 10.1136/sti.74.2.101

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  130 in total

Review 1.  Cervical cancer: is herpes simplex virus type II a cofactor?

Authors:  C Jones
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer.

Authors:  A Hildesheim; V Mann; L A Brinton; M Szklo; W C Reeves; W E Rawls
Journal:  Int J Cancer       Date:  1991-09-30       Impact factor: 7.396

3.  Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status.

Authors:  M R Mullokandov; N G Kholodilov; N B Atkin; R D Burk; A B Johnson; H P Klinger
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

4.  Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells.

Authors:  C D Woodworth; U Lichti; S Simpson; C H Evans; J A DiPaolo
Journal:  Cancer Res       Date:  1992-01-15       Impact factor: 12.701

5.  High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women.

Authors:  J C Johnson; A F Burnett; G D Willet; M A Young; J Doniger
Journal:  Obstet Gynecol       Date:  1992-03       Impact factor: 7.661

6.  The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus.

Authors:  P Leechanachai; L Banks; F Moreau; G Matlashewski
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

7.  Human papillomavirus type 16 and 18 gene expression in cervical neoplasias.

Authors:  M H Stoler; C R Rhodes; A Whitbeck; S M Wolinsky; L T Chow; T R Broker
Journal:  Hum Pathol       Date:  1992-02       Impact factor: 3.466

8.  Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types.

Authors:  A T Lorincz; R Reid; A B Jenson; M D Greenberg; W Lancaster; R J Kurman
Journal:  Obstet Gynecol       Date:  1992-03       Impact factor: 7.661

9.  Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity.

Authors:  H Romanczuk; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  9 in total

1.  Loss of sequences on the short arm of chromosome 17 is a late event in squamous carcinoma of the cervix.

Authors:  C S Herrington; M Worsham; S A Southern; P Mackowiak; S R Wolman
Journal:  Mol Pathol       Date:  2001-06

2.  Human papillomavirus in pterygium.

Authors:  M J Gallagher; A Giannoudis; C S Herrington; P Hiscott
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

3.  Infection and cervical neoplasia: facts and fiction.

Authors:  Wael I Al-Daraji; John Hf Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-04-28

4.  Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix.

Authors:  A Giannoudis; M Duin; P J Snijders; C S Herrington
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

5.  Glucose-Related Protein 78 Expression and Its Effects on Cisplatin-Resistance in Cervical Cancer.

Authors:  Chengyan Luo; Wen Fan; Yi Jiang; Shulin Zhou; Wenjun Cheng
Journal:  Med Sci Monit       Date:  2018-04-13

6.  The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1.

Authors:  Jiqin Xu; Hongyun Wang; Huiyan Wang; Qing Chen; Li Zhang; Chao Song; Qianqian Zhou; Ying Hong
Journal:  Hereditas       Date:  2019-04-09       Impact factor: 3.271

7.  Inequalities in the incidence of cervical cancer in South East England 2001-2005: an investigation of population risk factors.

Authors:  Laura G Currin; Ruth H Jack; Karen M Linklater; Vivian Mak; Henrik Møller; Elizabeth A Davies
Journal:  BMC Public Health       Date:  2009-02-20       Impact factor: 3.295

8.  Evaluation of adjunctive HPV testing by Hybrid Capture II in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy.

Authors:  Andrea Guyot; Shakir Karim; May S Kyi; John Fox
Journal:  BMC Infect Dis       Date:  2003-09-25       Impact factor: 3.090

9.  Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999-2014).

Authors:  Sen Li; Xi Wen
Journal:  BMC Cancer       Date:  2017-11-07       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.